Towards Healthcare

Cell and Gene Therapy Drug Delivery Devices Key Players and Leadership Alignment with Trends

Date : 15 October 2025

Top Companies in the Cell and Gene Therapy Drug Delivery Devices Market

Cell and Gene Therapy Drug Delivery Devices Market Companies

  • Baxter International
  • Becton, Dickinson & Company (BD)
  • B. Braun Melsungen
  • Terumo Corporation
  • Medtronic
  • ICU Medical
  • West Pharmaceutical Services
  • Stevanato Group
  • Gerresheimer
  • Ypsomed
  • SHL Medical / Enable Injections
  • Catalent Pharma Solutions
  • Sartorius
  • Thermo Fisher Scientific
  • Lonza
  • Miltenyi Biotec
  • Fresenius Kabi
  • Peli BioThermal
  • Sagent Pharmaceuticals / Nemera
  • Corin / Catheter & micro-delivery specialists/niche OEMs

Market Growth

The global cell and gene therapy drug delivery devices market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.

Strategic Announcements and Milestones: The rollout of innovative delivery platforms and automated devices is transforming therapy manufacturing and administration. These launches improve precision, reduce costs and contamination risks, and expand access to cell and gene therapies across wider patient populations.

  • In April 2025, AGC Biologics introduced its new Cell and Gene Technologies Division to strengthen and expand its advanced therapy services. This division is designed to enhance the company’s expertise, providing specialized support and scientific capabilities, further establishing AGC as a leading global CDMO in cell and gene therapies.
  • Launches of Advanced Delivery Platforms: Strategic announcements regarding facility expansions, new funding, and regulatory milestones highlight strong industry commitment. Such updates boost investor confidence, showcase technological progress, and drive global adoption of next-generation drug delivery devices.
  • In January 2024, Israeli biotech firm Pluri launched PluriCDMO, a new division dedicated to contract development and manufacturing services for cell therapies. Equipped with a 47,000-square-foot GMP-certified facility, the branch aims to deliver large-scale, high-quality cell therapy production to support the growing global demand.

Cell and Gene Therapy Drug Delivery Devices Market Value Chain Analysis

R&D

R&D in cell and gene therapy drug delivery devices aims to develop systems that accurately deliver modified cells and gene-editing tools, enhancing treatment effectiveness while addressing manufacturing and safety challenges.

Packaging and Sterilization

Packaging and sterilization of cell and gene therapy devices use specialized materials and processes to ensure sterility, preserve product integrity, and maintain viability, particularly during ultra-low and cryogenic storage.

Patient Support and Services

Patient support services for cell and gene therapy delivery devices provide personalized guidance, educational materials, financial aid, and logistical assistance to help patients navigate the complexities of treatment from start to finish.

Latest Announcement by Industry Leaders

In May 2024, ProPharma, a U.S.-based regulatory and compliance services provider, partnered with Italy’s PBL to launch the Cell Factory Box (CF Box), an enclosed, fully automated device for decentralized manufacturing of all cell and gene therapies (CGTs) in Class D (ISO8) or controlled areas. Eleonora Casucci, ProPharma’s VP of Quality & Compliance EU, stated that “many are adopting a decentralized approach to manufacturing [CGTs],” and highlighted that the CF Box offers significant advantages over existing devices, strengthening their position in the CGT market.

Recent Developments in the Cell and Gene Therapy Drug Delivery Devices Market

  • In May 2025, eXmoor Pharma formed a strategic partnership with KU Leuven to establish a new cell and gene therapy hub. The collaboration aims to combine scientific, regulatory, and manufacturing expertise to fast-track the development of innovative therapies from research to clinical trials.
  • In February 2024, UT Southwestern partnered with Pfizer to advance RNA delivery technologies. The collaboration aims to improve genetic medicine research, integrate AI-driven design approaches, and foster the development of new delivery methods for more effective therapeutic applications.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com